Commercial execution is still too often treated as something that happens after the science succeeds - when in reality, launch readiness, capital allocation and execution discipline can have a major impact on valuation, investor confidence and long-term commercial success.
This is a focused 45-minute session exploring how predictive launch intelligence and better orchestration can help biotech and pharma companies:
- De-risk commercial execution
- Improve launch readiness and coordination
- Accelerate time to market
- Protect launch value and capital efficiency
